Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin Effect of Combination With Oral L-Arginine by Böger, Gerhild I. et al.
3
d
g
(
t
o
m
F
P
U
s
B
d
R
a
Journal of the American College of Cardiology Vol. 49, No. 23, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PEndothelial Function
Asymmetric Dimethylarginine
Determines the Improvement of
Endothelium-Dependent Vasodilation by Simvastatin
Effect of Combination With Oral L-Arginine
Gerhild I. Böger, PHD,* Tanja K. Rudolph, MD,*† Renke Maas, MD,* Edzard Schwedhelm, PHD,*
Ekaterina Dumbadze,* Anneke Bierend,* Ralf A. Benndorf, MD,* Rainer H. Böger, MD*
Hamburg, Germany
Objectives We hypothesized that the level of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial
nitric oxide (NO) synthase (eNOS), might determine the endothelial effects of statins.
Background Endothelial NO synthase is up-regulated by statins. However, statins failed to improve endothelial function
in some studies. Asymmetric dimethylarginine inhibits eNOS by a mechanism that is reversible by
L-arginine.
Methods Ninety-eight clinically asymptomatic elderly subjects had their plasma ADMA levels screened. Those in the high-
est (high ADMA, n  15) and lowest quartiles of the ADMA distribution (low ADMA, n  13) were eligible to re-
ceive, in a randomized order, simvastatin (40 mg/day), L-arginine (3 g/day), or a combination of both, each for
3 weeks. Endothelium-dependent vasodilation (EDD) was assessed by brachial artery ultrasound.
Results Simvastatin had no effect on EDD in subjects with high ADMA (6.2  1.2% vs. 6.1  0.9%), whereas simvasta-
tin plus L-arginine significantly improved EDD (9.8  1.5% vs. 5.3  0.8%; p  0.01). In subjects with low
ADMA, simvastatin improved endothelial function when given alone (9.5  3.2% vs. 6.1  3.8%; p  0.001) or
in combination with L-arginine (9.0  3.1% vs. 6.3  3.3%; p  0.001). L-arginine alone improved endothelial
function in both groups. Endothelium-independent vasodilation was not affected.
Conclusions Simvastatin does not enhance endothelial function in subjects with elevated ADMA, whereas it does so in pa-
tients with low ADMA. Combination of simvastatin with oral L-arginine improves endothelial function in subjects
with high ADMA, but has no additional effect in subjects with low ADMA. As NO-mediated effects may play a
major role in the therapeutic effects of statins, ADMA concentration is an important factor that influences the
“pleiotropic” effects of simvastatin. (J Am Coll Cardiol 2007;49:2274–82) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.051c
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l-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
uctase inhibitors (statins) have been shown to enhance
ene expression of endothelial nitric oxide (NO) synthase
eNOS), due to inhibition of post-translational modifica-
ion of Rho proteins (1). This effect, which has also been
bserved with simvastatin (1), is suggested to mediate a
ajor part of the statins’ protective effects in the cardiovas-
rom the *Clinical Pharmacology Unit, Institute of Experimental and Clinical
harmacology, and the †Department of Cardiology, University Heart Center,
niversity Hospital Hamburg-Eppendorf, Hamburg, Germany. This study was
upported, in part, by eNOS Pharmaceuticals, Inc., Cambridge, Massachusetts. Drs.
öger, Maas, Schwedhelm, and Benndorf have a share in patents on asymmetric
imethylarginine assays and receive royalties from the licenses. Drs. Böger and
udolph contributed equally to this work.p
Manuscript received June 16, 2006; revised manuscript received February 7, 2007,
ccepted February 13, 2007.ular system (2). Up-regulation of eNOS messenger ribo-
ucleic acid is the result of enhanced eNOS messenger
ibonucleic acid stability in the presence of statins. This
NOS up-regulation has been suggested to also mediate the
nhanced endothelium-dependent, NO-mediated vasodila-
ion observed with statins in various animal models of
ypercholesterolemia (3–5), as well as in hypercholester-
lemic human subjects (6,7).
However, improvement of endothelium-dependent vaso-
ilation has not been consistently observed in all studies
erformed with simvastatin. For example, Vita et al. (8)
eported that 6 months of treatment with 40 mg/day of
imvastatin did not improve endothelium-dependent coro-
ary microvessel dilation despite a significant reduction in
ow-density lipoprotein (LDL) cholesterol. Failure to im-
rove endothelium-dependent vasodilation was also ob-
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June 12, 2007:2274–82 Simvastatin, L-Arginine, and Endothelial Functionerved with other statins (9). The reason why in some
tudies statins had no beneficial effect on the endothelium
as remained poorly understood.
The eNOS is the key enzyme in the biosynthesis of NO in
ndothelial cells; it metabolizes L-arginine to NO and
-citrulline (10). Asymmetric dimethylarginine (ADMA) is
n endogenous inhibitor of eNOS (11). Asymmetric dim-
thylarginine levels have been found to be elevated in
atients with cardiovascular risk factors like hypertension,
iabetes, hypercholesterolemia, and hyperhomocysteinemia
12–14). Moreover, high ADMA levels have been related to
ardiovascular diseases such as peripheral artery disease,
troke, and congestive heart failure (15); both experimen-
ally and clinically, high ADMA levels are associated with
ndothelial dysfunction (16). The inhibitory effect of
DMA on NOS activity can be overcome by this enzyme’s
atural substrate, L-arginine, suggesting that ADMA is a
ompetitive inhibitor (17).
Recently, Janatuinen et al. (18) reported that improve-
ent of myocardial blood flow by pravastatin was primarily
ependent on the circulating ADMA concentration. In
heir study, subjects with ADMA levels below the median
f the distribution (i.e., 0.3 mol/l) experienced improve-
ent of myocardial blood flow after statin therapy, whereas
hose with ADMA above the median did not benefit from
tatin treatment. This intriguing finding suggests that in
ubjects with elevated ADMA concentration, up-regulation
f eNOS by statins may remain without the expected
unctional consequences (i.e., improvement of endothelium-
ependent vasodilation), as the enzyme will be blocked by
he endogenous inhibitor of its activity, ADMA (17). These
bservations led us to hypothesize that statins will not
mprove endothelium-dependent vasodilation in patients
elected for the presence of high circulating ADMA con-
entrations, whereas this effect will be present in patients
ith low ADMA levels. In the former group of subjects,
dditional supplementation with L-arginine will uncover
he statin’s effect on endothelial function, whereas in the
atter group there will be no additional effect. This hypoth-
sis was investigated in 2 parallel studies including patients
ith high or low ADMA levels.
ethods
creening for ADMA concentration. Ninety-eight clini-
ally healthy elderly subjects were invited to participate in a
creening blood sampling for circulating ADMA levels. All
f these subjects filled a structured health questionnaire and
ad a peripheral venous blood sample drawn for analysis of
DMA. Due to the lack of reference ranges for ADMA at
he time when this study was initiated, we predefined the
ighest quartile of the ADMA distribution to be “elevated
DMA,” and the lowest quartile of the distribution to be
low ADMA.”
atients and study protocol. This trial was carried out athe Institute of Experimental and Clinical Pharmacology
D
snd Toxicology of the University
ospital Hamburg-Eppendorf
n accordance with the principles
utlined in the Declaration of
elsinki. The study protocol was
pproved by the local ethics com-
ittee, and all volunteers gave
heir written informed consent
efore enrollment.
Subjects who were allocated to
he highest or lowest quartiles of
he distribution of ADMA plasma
evels in the screened population
ere consecutively invited into
he study center until as many
atients had agreed to participate
s required by the sample size calculation, with a few
dditional subjects to account for potential drop-outs. The
tudy consisted of 2 parts: in the first study, 15 subjects with
DMA levels within the highest quartile of the distribution
articipated. Clinically healthy male and female volunteers
ere included, age between 45 to 85 years. In the second
tudy, 13 clinically healthy female and male volunteers age
etween 45 and 85 years with low plasma ADMA concen-
ration were enrolled. Major exclusion criteria for all study
articipants were cardiovascular disease, diabetes mellitus,
evere hypercholesterolemia, renal or liver insufficiency,
egular intake of platelet aggregation inhibitors or HMG-
oA reductase inhibitors, hormone replacement therapy,
levation of creatinine kinase 1.5 times above the upper
imit of the normal range, and all other acute or chronic
iseases. All criteria were assessed by clinical examination,
lood tests, and interview 1 week before the first study day.
emographic and anthropometric characteristics of both
roups are given in Table 1.
Both studies were performed as observer-blinded, ran-
omized, 3-period crossover trials.
emographic and Anthropometric Data
Table 1 Demographic and Anthropometric Data
High ADMA
(n  15)
Low ADMA
(n  13)
Gender (M/F) 11/4 5/8
Age (yrs) 59.6 (4.2) 54.5 (7.9)
Height (cm) 171.7 (6.7) 171.6 (9.7)
Weight (kg) 74.2 (11.6) 73.4 (12.7)
Current smokers (n)* 1 3
Diabetes mellitus (n)* 0 0
Hypertension (n)* 0 0
Hypercholesterolemia (n)* 12 6
Obesity (n)* 3 1
Systolic blood pressure (mm Hg) 140.5 (17.6) 118.1 (16.7)
Diastolic blood pressure (mm Hg) 83.3 (7.0) 76.5 (7.5)
Heart rate (1/min) 70.5 (10.9) 63.6 (7.0)
Abbreviations
and Acronyms
ADMA  asymmetric
dimethylarginine
eNOS  endothelial nitric
oxide synthase
FMD  flow-mediated
dilation
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
LDL  low-density
lipoprotein
NO  nitric oxide
SR  sustained releaseata are mean (SEM) or absolute numbers, as indicated.
ubject.*More than 1 risk factor may apply per
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Simvastatin, L-Arginine, and Endothelial Function June 12, 2007:2274–82After a 12-h overnight fast, each volunteer presented at
he investigational clinic in the morning of the first study
ay. Blood and urine samples were taken.
Serum total cholesterol, LDL and high-density lipopro-
ein cholesterol, triglyceride levels, and serum creatinine,
reatine kinase, as well as uric acid concentrations were
etermined immediately by standard laboratory methods
sing certified assays. Serum concentrations of high sensi-
ive C-reactive protein were quantified by using a highly
ensitive nephelometric assay method (Dade Behring, Esch-
orn, Germany). Urine samples were aliquoted and stored at
20°C until analysis.
After vascular function testing as described in the follow-
ng text, volunteers received their medication for the first
reatment period of 21 days. Medication was, in randomized
rder, either simvastatin (orally, every day, 40 mg/day;
erck, Sharp and Dohme, Munich, Germany), L-arginine
ustained release (L-arginine SR; orally, 1.5 g twice a day;
NOS Pharmaceuticals, Inc., Cambridge, Massachusetts),
r the combination of simvastatin plus L-arginine SR. After
1 days of drug intake, subjects returned to the clinic and
nderwent the same investigational procedures as on day 1.
fter at least 3 weeks of washout, patients received the
econd medication for 21 days, and after another washout
eriod, patients received the third medication in an identical
tudy design. Thus, each patient received each of the
edications in randomized order. Repeat testing of all study
arameters including ultrasound analysis of the brachial
rtery was performed before and after each treatment
eriod, and treatment effects were always related to individ-
al baseline data before each treatment period. The last dose
f simvastatin medication was taken on the evening before
tudy parameters were assessed; the last dose of L-arginine
R was taken in the early morning of the study day.
ndothelium-dependent vasodilation in the brachial
rtery. Endothelium-dependent vasodilation was deter-
ined by high-resolution ultrasound of the brachial artery
ccording to the principles set by the international brachial
rtery reactivity task force (19). Brachial artery diameter was
etermined at baseline after at least 20 min of resting in the
upine position arm in a quiet, temperature-controlled room
22  2°C) by high-resolution ultrasound (12-MHz linear
rray transducer; Siena, Siemens, Germany). Longitudinal
cans of the brachial artery were obtained approximately 5
m proximal of the antecubital fossa. The transmit focus
one was set at the depth of the anterior wall. A view of a
-cm longitudinal section of the brachial artery was re-
orded on S-VHS for 30 s at baseline and before and during
eak (1 min) reactive hyperemia (induced by deflation of a
lood pressure cuff previously inflated to 50 mm Hg above
he subject’s systolic blood pressure around the forearm for
min). Each 30-s recording was digitized (Vascular Imager
.1.3, Medical Imaging Applications LLC, Coralville,
owa) at a rate of 10 high-resolution frames per s (300
rames per recording), using as specialized software (Bra-
hial Analyzer 4.1.3, Medical Imaging Applications LLC). ehis allowed the averaging of vessel diameter from 25 to 40
eart beats.
Endothelium-dependent, flow-mediated dilation (FMD)
as calculated as the percent change in diameter 1 min after
uff release relative to the baseline diameter before cuff
elease. Endothelium-independent vasodilation was deter-
ined as the difference between a second baseline diameter
easurement and the maximum arterial diameter after 0.4
g of sublingual glycerol trinitrate. Anatomical landmarks
nd snapshot images were used to assess FMD in the exact
ame vessel section on each study day and at each time
oint.
The mean intraindividual coefficient of variation of the
aseline diameter of the brachial artery of the baseline
easurements obtained on the 3 separate study days (rep-
esenting the cumulative intraindividual day-to-day varia-
ion of the vessel diameter as well and the intra- and
nterobserver variation in measurement) was 4.20% and
.75%, respectively, in the 2 studies.
lasma concentrations of ADMA. Asymmetric dimethyl-
rginine concentration was determined in plasma by means
f a previously described, validated high-performance liquid
hromatography method (14) after extraction of plasma
amples on carboxylic acid solid phase extraction cartridges
Varian, Harbor City). Quality control sera were analyzed
egularly throughout the course of this study; the coefficients
f variation in this study were 1.65% intra-assay and 2.49%
nterassay for ADMA, 1.85% intra-assay and 3.91% inter-
ssay for symmetric dimethylarginine (SDMA), and 1.71%
ntra-assay and 2.97% interassay for L-arginine; the limit of
uantitation was 0.04 mol/l.
alculations and statistical analyses. Data are given as
ean  SEM. All data were tested for normal distribution
ith the Kolmogorov-Smirnov test. Analysis of covariance
as performed for the main efficacy parameters with treat-
ent, period, sequence, and subject within sequence as
ain effects and pretreatment level as a covariate. Statisti-
ally significant differences between treatments were tested
y analysis of variance followed by the Scheffé test for
epeated measurements. An adjusted value of p  0.05 was
onsidered to be statistically significant. All calculations
ere performed with StatView version 12.0 (Cary, North
arolina) or SPSS (Chicago, Illinois) version 12.0.
Primary target variable was the intraindividual compari-
on of the study-medication-induced change in FMD
efore and after treatment with simvastatin, L-arginine, and
combination of simvastatin and L-arginine. We aimed to
etect a minimal difference in the primary target variable of
he mean study-medication-induced change in FMD be-
ween the treatment of 30% (in relative terms) with a
-sided type I error protection of 0.05 and a power of 0.80.
ased on previous trials and pilot data, we estimated the SD
f the difference between the 2 values for the same patient
o range from 20% to 50% (in relative terms), which gave a
ormal sample size requirement of 12 individuals for
ach group.
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June 12, 2007:2274–82 Simvastatin, L-Arginine, and Endothelial Functionesults
istribution of ADMA plasma concentrations in the
creened population. Figure 1A displays the distribution
f ADMA levels in the population of 98 subjects that were
creened; cutoff levels for the highest and lowest quartiles
re also indicated. Mean ADMA in the total screened
opulation was 0.41 0.10 mol/l; mean ADMA in the 15
ubjects who participated in study A was 0.56  0.06
mol/l. By comparison, mean ADMA concentration in the
ubjects who participated in study B was 0.29  0.05
mol/l (Fig. 1B).
ffects of simvastatin, L-arginine, and their combination
n endothelium-dependent vasodilation in subjects with
igh ADMA concentration (study A). Simvastatin alone
ad no significant effect on endothelium-dependent vaso-
ilation (6.08  0.94% vs. 6.16  1.21% at baseline; p 
S). L-arginine SR enhanced endothelium-dependent va-
odilation significantly (8.19  0.87% vs. 4.88  0.79% at
aseline; p  0.05). The greatest improvement in
ndothelium-dependent vasodilation, however, was induced
y the combination of simvastatin plus L-arginine SR (9.89
1.51% vs. 5.32  0.84% at baseline; p  0.01) (Fig. 2A).
he effect of the combination of simvastatin plus
-arginine on endothelium-dependent vasodilation was
ignificantly greater than that of either simvastatin alone
p  0.024) or L-arginine SR alone (p  0.048). Despite
he variability of baseline FMD, there were no significant
equence effects between the treatment periods. There
ere no significant differences in brachial artery diameter
Figure 1 Distribution of Circulating ADMA Concentrations
(A) Distribution of circulating asymmetric dimethylarginine (ADMA) concentrations
median (solid line), which was 0.39 mol/l, and the 25th and 75th percentiles (d
nine levels in study participants. Mean and SD in the 2 groups are marked by a horizo
B, filled circles indicate subjects with high ADMA and unfilled circles indicate subjectefore and after each treatment, or between groups ssimvastatin 4.73  0.17 mm to 4.79  0.17 mm; L-arginine
.60 0.16 mm to 4.59 0.14 mm; combination 4.75 0.19
m to 4.74 0.17 mm; all pNS). No significant carryover
ffects of the treatments were detected.
Endothelium-independent vasodilation induced by glyc-
rol trinitrate was not significantly affected by any of the
reatments (Fig. 2B).
ffects of simvastatin, L-arginine, and their combination
n endothelium-dependent vasodilation in subjects with
ow ADMA concentration (study B). Administration of
imvastatin, L-arginine, as well as their combination each led
o a significant increase in endothelium-dependent vasodila-
ion (simvastatin 9.47  3.16% vs. 6.08  3.77% at baseline;
 0.001; L-arginine 10.16  2.85% vs. 5.69  2.99% at
aseline; p 0.02; simvastatin L-arginine 8.99 3.06% vs.
.34  3.26% at baseline; p  0.001) (Fig. 3A).
There were no significant differences in brachial artery
iameter before and after each treatment, or between groups
simvastatin 4.43  0.76 mm to 4.32  0.61 mm; L-arginine
.42  0.75 mm to 4.33  0.62 mm; simvastatin 
-arginine 4.29 0.70 mm to 4.31 0.77 mm; all pNS).
here were no significant changes of systolic or diastolic blood
ressure or heart rate after any of the treatments. No significant
arryover effects of the treatments were detected.
Endothelium-independent vasodilation induced by glyc-
rol trinitrate was not significantly affected by any of the
reatments (Fig. 3B).
DMA, SDMA, and L-arginine plasma concentrations.
symmetric dimethylarginine concentration was neither
hort of 98 clinically healthy ambulatory subjects. Vertical lines indicate the
lines; 0.35 mol/l and 0.48 mol/l, respectively). (B) Asymmetric dimethylargi-
ar and vertical line, respectively. Each subject is represented by a circle. In panel
low ADMA.in a co
ashed
ntal b
s withignificantly influenced by simvastatin treatment nor by
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Simvastatin, L-Arginine, and Endothelial Function June 12, 2007:2274–82-arginine SR supplementation in either of the groups (data
ot shown). During supplementation with L-arginine SR,
-arginine plasma concentration increased in both groups,
esulting in significantly elevated L-arginine/ADMA ratio.
DMA plasma concentration remained stable during the
tudy. There was a significant inverse relationship between
DMA plasma levels and the improvement of endothelium-
ependent vasodilation by simvastatin (Fig. 4).
ipoprotein and clinical chemistry profiles. Simvastatin
ignificantly reduced LDL cholesterol by 42 4% and 47
Figure 2 Effects of Simvastatin, L-Arginine, and Their Combinat
on Endothelium-Dependent and -Independent Vasodila
Endothelium-dependent (A) and endothelium-independent vasodilation (B) in the b
treatment with simvastatin, L-arginine sustained release (SR), or their combination
0.05 versus baseline or between groups as indicated. Hatched bars  before trea
Figure 3 Effects of Simvastatin, L-Arginine, and Their Combinat
on Endothelium-Dependent and -Independent Vasodila
Endothelium-dependent (A) and endothelium-independent vasodilation (B) in the b
treatment with simvastatin, L-arginine SR, or their combination, in subjects with lo
cated. Hatched bars  before treatment; black bars  after treatment. Abbreviati%, respectively, when it was given alone or in combination
ith L-arginine SR in subjects with high ADMA (Table 2).
he respective ranges of reduction were 40  3% and 35 
% in subjects with low ADMA. L-arginine SR had no
ignificant effect on the lipoprotein profile when given
lone. There was a slight trend towards elevated serum
reatine kinase, aspartate aminotransferase, and alanine
minotransferase activities during simvastatin treatment ei-
her given alone or in combination with L-arginine SR, but
one of these serum enzyme activities reached a critical level
n Subjects With High ADMA
l artery as assessed by high-resolution ultrasound before and after 3 weeks of
bjects with elevated asymmetric dimethylarginine (ADMA) concentration. *p 
; black bars  after treatment. GTN  nitroglycerin; n.s.  not significant.
n Subjects With Low ADMA
l artery as assessed by high-resolution ultrasound before and after 3 weeks of
al ADMA concentration. *p  0.05 versus baseline or between groups as indi-
 in Figure 2.ion
tion i
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June 12, 2007:2274–82 Simvastatin, L-Arginine, and Endothelial Functionn any of the subjects. Two subjects with high ADMA
xperienced muscle pain during simvastatin administered
lone or in combination, and 5 subjects reported loose stools
r flatulence during L-arginine SR administered either
lone or in combination, but study medication was not
nterrupted in any of the participants. In subjects with low
DMA, no volunteer complained about side effects of
imvastatin administered alone or in combination, 3 volun-
eers reported loose stools or flatulence, and 1 volunteer
eported sleeping disturbance during L-arginine SR admin-
stered either alone or in combination, but study medication
as not interrupted in any of the participants.
Figure 4 Relationship Between Plasma ADMA Concentration
and the Endothelial Response to Simvastatin
Filled circles  subjects with high ADMA; unfilled circles  subjects with low
ADMA. ADMA  asymmetric dimethylarginine; FMD  flow-mediated dilation.
ipoprotein and C-Reactive Protein Levels
Table 2 Lipoprotein and C-Reactive Protein Levels
Variable
Simvastatin
Baseline After
Subjects with high ADMA
Total cholesterol (mg/dl) 258.1 (7.4) 181.7 (6.1)*
LDL cholesterol (mg/dl) 168.5 (7.7) 94.5 (5.7)*
HDL cholesterol (mg/dl) 56.8 (5.1) 58.0 (5.3)
Triglycerides (mg/dl) 165.1 (20.0) 140.2 (24.3)
C-reactive protein (U/l) 1.93 (1.35) 1.56 (0.80)
Subjects with low ADMA
Total cholesterol (mg/dl) 254.4 (45.0) 182.2 (28.1)*
LDL cholesterol (mg/dl) 162.6 (47.6) 90.8 (25.1)*
HDL cholesterol (mg/dl) 62.9 (25.2) 71.6 (19.2)
Triglycerides (mg/dl) 122.5 (55.1) 99.2 (44.2)*
C-reactive protein (U/l) 1.56 (1.06) 1.18 (0.63)ata are mean (SEM). *p  0.05 versus baseline.
ADMA  asymmetric dimethylarginine; HDL  high-density lipoprotein; LDL  low-density lipoprotein;-reactive protein. C-reactive protein concentration was
ot significantly affected by treatment with simvastatin or
-arginine SR in either of the groups. However, treatment
ith the combination of simvastatin and L-arginine SR
ignificantly reduced C-reactive protein concentration in
ubjects with high ADMA (1.9  0.3 vs. 2.7  1.3 mg/l at
aseline; p  0.05), but not in subjects with low ADMA
Table 2).
iscussion
he main finding of the present study is that the addition of
ral L-arginine SR to simvastatin improves endothelium-
ependent vasodilation in patients with elevated ADMA
oncentration, whereas simvastatin alone had no significant
ffect. Moreover, endothelium-dependent vasodilation was
ignificantly greater after combined treatment with simva-
tatin plus L-arginine than after L-arginine alone in this
roup. By contrast, in subjects with low ADMA, adminis-
ration of simvastatin alone, L-arginine alone, or their
ombination all significantly improved endothelium-
ependent vasodilation. There was no significant difference
n the extent of improvement of endothelial function be-
ween the 3 treatments in this group of subjects.
Improvement in endothelium-mediated blood flow in
esponse to statin treatment is believed to be mainly
ediated by up-regulation of eNOS (1). This mechanism
as been suggested to underlie the improvement in endo-
helial dysfunction by simvastatin or pravastatin in hyper-
holesterolemic rabbits (20), by simvastatin in hypercholes-
erolemic subjects (21) and heart transplant recipients (22),
nd the improvement in claudication distance induced by
torvastatin in patients with peripheral arterial occlusive
isease (23).
However, studies have not unanimously shown improve-
ent in endothelium-dependent vasodilation by statins:
here have been several studies with different statins and in
arying patient populations in which statin treatment did
L-Arginine SR Combination
aseline After Baseline After
6.0 (6.2) 244.1 (6.9) 256.9 (6.1) 167.9 (3.8)*
9.6 (4.9) 157.6 (6.8) 165.4 (5.5) 86.7 (4.0)*
4.3 (4.2) 54.1 (5.3) 55.7 (4.9) 58.5 (4.9)
1.1 (22.5) 162.0 (23.1) 178.2 (18.6) 113.7 (13.9)
.59 (3.22) 2.18 (2.76) 2.71 (4.87) 1.85 (1.2)
0.7 (36.5) 252.7 (45.5) 246.4 (50.3) 182.8 (24.7)*
5.9 (40.7) 159.3 (46.5) 153.4 (53.6) 92.3 (30.5)*
8.8 (18.9) 69.3 (17.1) 68.7 (18.7) 69.5 (16.0)
9.8 (83.9) 120.3 (50.8) 121.0 (73.6) 104.7 (52.2)
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lausible molecular explanation for these contradictory ob-
ervations was proposed.
Interestingly, the notion that statin treatment leads to
nhanced NO release via up-regulation of eNOS’s gene
xpression was implicitly based on the assumption that
NOS, once its protein level is up-regulated during statin
reatment, is enzymatically active. However, this may not
ecessarily be the case, as in contrast to in-vitro experimen-
al studies and animal experiments, endogenous inhibitors
f NO synthase have been shown to circulate in humans.
uch endogenous NOS inhibitors, like monomethyl-L-
rginine and ADMA, may block enzymatic activity of
NOS despite its up-regulation by statins and thereby
nnihilate the statins’ effect on endothelial function. Indeed,
anatuinen et al. (18) recently demonstrated that treatment
ith 40 mg/day of pravastatin for 6 months resulted in
mproved myocardial blood flow only in those patients who
ad circulating ADMA concentrations below the median
0.3 mol/l). Thus, ADMA (which is present at sufficiently
igh levels in humans, whereas monomethyl-L-arginine is
nly present in minor amounts in human plasma [26]) may
epresent one possible explanation for the contradictory
ndings of clinical studies on the statins’ effect on endothe-
ial function.
In our study, we have selected patients at the 2 extremes
f the ADMA distribution in a population of 98 elderly,
linically asymptomatic screenees in order to test the ther-
peutic implication of the hypothesis outlined above: if
DMA, a competitive inhibitor of NO synthase, prevents
he eNOS enzyme up-regulated by statins from being
ctive, then displacement of the inhibitor by excess concen-
rations of the natural substrate, L-arginine, should result in
significant enhancement of the statin’s effect on
ndothelium-mediated vasodilation in this group. Our re-
ults show that this is indeed the case. The combination of
imvastatin plus L-arginine SR produced the strongest
nhancement in endothelium-mediated vasodilation,
hereas simvastatin alone had no significant effect at all in
he study population selected for an elevated ADMA
oncentration. Furthermore, the combination of simvastatin
lus L-arginine SR also induced a slightly, but significantly,
reater improvement in endothelium-dependent vasodila-
ion than L-arginine SR alone. This latter observation adds
urther evidence to confirm the hypothesis that up-
egulation of eNOS gene expression plus supplementation
f its natural substrate enable improvement of endothelial
unction in patients with elevated ADMA concentration.
By contrast, in subjects with low plasma ADMA levels
hat were investigated in the second part of our study,
imvastatin alone significantly improved endothelium-
ependent vasodilation in a manner that was not further
nhanced by L-arginine. The extent of simvastatin’s effect
n the present study was comparable with that reported in
revious studies (7,27). Again, these data suggest that aDMA plays an important role in the regulation of NOS
ctivity and endothelial function in humans.
A previous experimental study has shown that L-arginine
ignificantly enhanced cerebral blood flow in an eNOS-
ependent manner in mice chronically treated with simva-
tatin (28). In this study, the combined effect of simvastatin
lus L-arginine was absent in genetically eNOS-deficient
ice, strongly supporting the important role of NO syn-
hase in this effect. Furthermore, the combination of
-arginine (7 g/day) plus simvastatin (20 mg/day) was
ssessed in a clinical study in 25 hypercholesterolemic
ubjects (29). In the latter study, a tendency towards a
tronger improvement of endothelium-dependent vasodila-
ion by simvastatin plus L-arginine was shown as compared
o simvastatin alone; however, this effect failed to reach
tatistical significance, probably because only 10 of 25
ubjects underwent ultrasound investigation, and because
essel diameters were assessed manually. By contrast, in our
tudy, a computer-aided image analysis software was used
or determination of vessel diameter as recommended in
urrent guidelines (19). Moreover, ADMA levels were not
easured in the study by Pereira et al. (29).
Subjects were included in the first part of our study if they
ad ADMA levels within the upper quartile of the distri-
ution of a group of 98 healthy elderly subjects. Thus, their
DMA levels were relatively high, but not necessarily
levated above what is now considered the normal range
30), and ADMA levels in subjects included in the second
art of our study were clearly at the lower margin of the
ormal range. Mean ADMA levels in the 2 groups in our
tudy were 0.29  0.05 mol/l and 0.56  0.06 mol/l,
espectively. The corresponding mean ADMA levels in the
groups of patients investigated by Janatuinen et al. (18)
ere 0.28  0.05 mol/l and 0.50  0.13 mol/l, respec-
ively (Dr. R. Laaksonen, personal communication, October
006).
Asymmetric dimethylarginine levels comparable to those
ound in subjects in the first part of our study have been
ound to be associated with an increased risk of cardiovas-
ular disease by various groups of investigators. Lu et al. (31)
eported that high ADMA levels (median, 0.75 mol/l)
ere prospectively associated with an increased risk of
xperiencing major adverse cardiovascular events in a group
f 153 patients with stable coronary heart disease undergo-
ng coronary angioplasty. In another large prospective clin-
cal study including 1,874 patients with stable coronary
eart disease, patients whose ADMA levels lay within the
ighest tertile of the distribution (ADMA concentration
0.70 mol/l) had a 2.5-fold elevated risk of major adverse
ardiovascular events or death (32). We found that ADMA
evels above 0.86 mol/l were associated with a 4-fold
levated risk of perioperative cardiac events in a population
f mixed cardiovascular risk (33).
The biochemical mechanism leading to high ADMA
evels in the present study has not been addressed. Reduced
ctivity of dimethylarginine dimethylaminohydrolase, the
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June 12, 2007:2274–82 Simvastatin, L-Arginine, and Endothelial Functionnzyme that inactivates ADMA (34), is one possible mech-
nism, as reduced renal excretory function was not detected
ccording to calculation of creatinine clearances.
Our study has several limitations: simvastatin treatment
as initiated based upon the hypothesis that ADMA may
odulate the endothelial response to statins, despite the fact
hat elevated ADMA concentration confers no indication
or statin treatment. We may, thus, have underestimated the
ffect of simvastatin on endothelium-dependent vasodila-
ion, as subjects were not specifically selected for the
resence of hypercholesterolemia in our study. However, 12
f 15 study participants with high ADMA had serum LDL
holesterol concentrations above 160 mg/dl, and none had a
erum LDL cholesterol concentration below 130 mg/dl. By
ontrast, only 6 of 13 participants with low ADMA had
ypercholesterolemia. This finding may relate to a frequent
oincidence of elevated ADMA and cholesterol concentra-
ions in the population, suggesting that many patients
reated with statins for their high cholesterol levels may also
isplay elevated ADMA concentration. We have reported
arlier that hypercholesterolemic patients, even when clin-
cally asymptomatic, are characterized by elevated ADMA
oncentration, which contributes to endothelial dysfunction
n a manner that is reversible by L-arginine (14). Elevated
DMA concentration was unaffected by statin treatment in
ur study, as was reported by others (18,29). This finding
ay point to the fact that elevation of ADMA concentra-
ion occurs independently of LDL cholesterol and that it is
ot affected by molecular pathways modulated by statins,
uch as the Rho kinase pathway (35).
The relatively small sample size and the short duration of
he study did not allow us to study clinical end points.
evertheless, it was sufficient to significantly detect clini-
ally relevant changes in endothelium-dependent vasodila-
ion. Flow-induced vasodilation by using the method we
pplied (i.e., upper-arm cuff inflation) as a surrogate of
ndothelium-mediated vasodilation is not exclusively NO-
ependent (19,36,37). Thus, the possible “dilution” of any
ffects on endothelial NO formation by pharmacologic
ntervention due to non–NO-mediated vasodilation may
ave reduced the sensitivity to detect changes in the main
nd point. The significant change in flow-mediated vasodi-
ation that we observed after L-arginine alone or in combi-
ation with simvastatin shows that our method was sensitive
nough to detect clinically relevant changes in endothelial
unction. Finally, we do not have data available from this
tudy to show that exogenous L-arginine resulted in a
ignificant elevation of intracellular L-arginine levels. How-
ver, in a recent study, we were able to show by means of
table isotope labelling that exogenously applied L-arginine
s being taken up readily into cells with no difference
etween hypercholesterolemic and control animals (38), and
hat the ratio of L-arginine over ADMA may determine
ndothelial function.
1onclusions
ur study provides evidence that the endogenous inhibitor
f NO synthase, ADMA, may not only be a novel,
ndependent cardiovascular risk marker as demonstrated in
ther recent studies (31–33,39) and summarized in several
eviews (15,16), but high ADMA levels may also diminish
he ability of statins to improve endothelium-dependent
asodilation. Evidence in favor of our hypothesis is
trengthened by a parallel study that shows that this effect of
imvastatin is retained in subjects from the same population,
ut with low normal ADMA levels. As the ability of statins
o improve endothelial function has been suggested to be a
ajor contributor to this class of drugs’ beneficial effects on
orbidity and mortality, further studies should address the
uestion whether ADMA concentration should be moni-
ored before initiating statin treatment, and addition of
-arginine might be considered in patients with elevated
DMA levels.
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